Sexually transmitted diseases · 2025
High Incidence of Curable Sexually Transmitted Infections Among Persons Accessing Oral Preexposure Prophylaxis at an Integrated Sexually Transmitted Infection/Preexposure Prophylaxis Clinic in Lilongwe, Malawi.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rutstein Sarah E, Chen Jane S, Jere Edward, Limarzi-Klyn Laura, Mphande Zakaliah, Mathiya Esther, Nyirenda Naomi, Banda Gabriel, Mulholland Grace E, Hosseinipour Mina C, Hoffman Irving F, Matoga Mitch
Аннотация
BACKGROUND: Understanding the burden of incident sexually transmitted infections (STIs) among persons in Eastern and Southern Africa after initiating HIV preexposure prophylaxis (PrEP) is critical to allocate scarce STI testing and HIV prevention resources.
METHODS: Participants were recruited from an STI clinic in Lilongwe, Malawi (March-December 2022). Eligibility reflected oral PrEP eligibility per contemporary guidelines, limited to persons seeking STI services. We enrolled 3 groups: "index participants" who initiated PrEP, "PrEP-eligible decliners" who declined PrEP, and PrEP-initiating "referred partners" referred by index participants. Surveys and PrEP use assessments were conducted at baseline and at 1, 3, and 6 months; Chlamydia trachomatis, Neisseria gonorrhoeae, and syphilis testing done at baseline and at 3 and 6 months. A subset of participants completed in-depth interviews that were thematically analyzed.
RESULTS: We enrolled 238 participants (174 index, 37 PrEP-eligible decliners, 27 referred partners); most were male (58%), and the median age was 27 years (interquartile range, 22-31 years). Forty-seven incident STIs were identified during 89.3 person-years (py) of follow-up (52.6/100 py). Men had a higher incidence versus women (55.8/100 py vs. 48.6/100 py). Index participants had the highest STI incidence (61.3/100 py), compared with PrEP-eligible decliners (26.4/100 py) and referred partners (27.1/100 py). Most incident infections were asymptomatic. Nearly all 27 interviewed participants described an STI as related to perceived HIV risk and need for PrEP.
CONCLUSIONS: Incident, asymptomatic STIs in the 6 months after PrEP initiation were common. Testing of STI contextualizes perceived HIV risk and may encourage PrEP persistence. Integrating bacterial STI testing within PrEP care may reduce transmission via expedient treatment and should be considered alongside PrEP program expansion.Clinical Trial Number: NCT05307991 ( https://clinicaltrials.gov/ct2/show/NCT05307991 ).
METHODS: Participants were recruited from an STI clinic in Lilongwe, Malawi (March-December 2022). Eligibility reflected oral PrEP eligibility per contemporary guidelines, limited to persons seeking STI services. We enrolled 3 groups: "index participants" who initiated PrEP, "PrEP-eligible decliners" who declined PrEP, and PrEP-initiating "referred partners" referred by index participants. Surveys and PrEP use assessments were conducted at baseline and at 1, 3, and 6 months; Chlamydia trachomatis, Neisseria gonorrhoeae, and syphilis testing done at baseline and at 3 and 6 months. A subset of participants completed in-depth interviews that were thematically analyzed.
RESULTS: We enrolled 238 participants (174 index, 37 PrEP-eligible decliners, 27 referred partners); most were male (58%), and the median age was 27 years (interquartile range, 22-31 years). Forty-seven incident STIs were identified during 89.3 person-years (py) of follow-up (52.6/100 py). Men had a higher incidence versus women (55.8/100 py vs. 48.6/100 py). Index participants had the highest STI incidence (61.3/100 py), compared with PrEP-eligible decliners (26.4/100 py) and referred partners (27.1/100 py). Most incident infections were asymptomatic. Nearly all 27 interviewed participants described an STI as related to perceived HIV risk and need for PrEP.
CONCLUSIONS: Incident, asymptomatic STIs in the 6 months after PrEP initiation were common. Testing of STI contextualizes perceived HIV risk and may encourage PrEP persistence. Integrating bacterial STI testing within PrEP care may reduce transmission via expedient treatment and should be considered alongside PrEP program expansion.Clinical Trial Number: NCT05307991 ( https://clinicaltrials.gov/ct2/show/NCT05307991 ).